Sanofi to Close Irish Plant
ePT--the Electronic Newsletter of Pharmaceutical Technology
Paris (Mar. 15)-Sanofi-Aventis plans to close its manufacturing site in Waterford, Ireland.
Paris (Mar. 15)-Sanofi-Aventis (www.sanofi-aventis.com) plans to close its manufacturing site in Waterford, Ireland.
The company attributes the closure to increasing pressure from generics. Sanofi came to the decision after evaluating its plant network and concluding that other sites had excess capacity and could take over the manufacturing currently performed at the Waterford site with minimal extra investment.
The Waterford plant currently manufactures mature and over-the-counter products, including “Essentiale” for liver protection and “Flagyl” for microbial infections. Manufacture of these two products will be taken over by Sanofi plants in France and Germany.
The site is expected to close by the end of the year, with the loss of about 200 jobs.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Entering New Domains for 3D Printing of Drug Products
April 6th 20253D printing of personalized medications is currently possible under existing compounding regulations, offering enhanced process control through automation. But new legislation coming in 2025 will allow 3D printing as part of a distributed manufacturing framework.
